Cover Image
市場調查報告書

念珠菌陰道炎 : 開發平台分析

Vulvovaginal Candidiasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229808
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
念珠菌陰道炎 : 開發平台分析 Vulvovaginal Candidiasis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 63 Pages
簡介

所謂念珠菌陰道炎,是陰道內念珠菌真菌異常增生,造成發炎的疾病。 症狀有陰道和外陰部發癢和刺痛感,加熱感。粥狀,酒糟狀之分泌物增加,外陰部可見的紅色皮疹等,甚至會擴張到恥骨,鼠蹊部,大腿部週邊。

本報告提供念珠菌陰道炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關最新的新聞和發表,以及正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

念珠菌陰道炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

治療藥的開發企業

  • Grupo Ferrer Internacional, S.A.
  • NovaDigm Therapeutics, Inc.
  • Viamet Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • arasertaconazole
  • CD-101
  • Myc-102
  • NDV-3
  • NDV-3A
  • VT-1161

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8459IDB

Summary

Global Markets Direct's, 'Vulvovaginal Candidiasis - Pipeline Review, H2 2016', provides an overview of the Vulvovaginal Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
  • The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects
  • The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Vulvovaginal Candidiasis Overview
  • Therapeutics Development
    • Pipeline Products for Vulvovaginal Candidiasis - Overview
  • Vulvovaginal Candidiasis - Therapeutics under Development by Companies
  • Vulvovaginal Candidiasis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Vulvovaginal Candidiasis - Products under Development by Companies
  • Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development
    • Cidara Therapeutics, Inc.
    • Grupo Ferrer Internacional, S.A.
    • NovaDigm Therapeutics, Inc.
    • Scynexis, Inc.
    • TGV-Laboratories
    • Viamet Pharmaceuticals, Inc.
  • Vulvovaginal Candidiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (clotrimazole + diclofenac sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arasertaconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CD-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MH-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Myc-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDV-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NDV-3A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SCY-078 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TOL-463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VT-1161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Vulvovaginal Candidiasis - Dormant Projects
  • Vulvovaginal Candidiasis - Discontinued Products
  • Vulvovaginal Candidiasis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis
      • Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
      • Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting
      • Aug 08, 2016: SCYNEXIS Reports Second Quarter 2016 Financial Results and Provides Company Update
      • Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis
      • Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016
      • Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors
      • May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate
      • Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis
      • Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections
      • Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV
      • Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis
      • Jul 29, 2015: Viamet to Present at Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting
      • Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015
      • Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Vulvovaginal Candidiasis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Vulvovaginal Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016
  • Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
  • Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016
  • Vulvovaginal Candidiasis - Pipeline by Scynexis, Inc., H2 2016
  • Vulvovaginal Candidiasis - Pipeline by TGV-Laboratories, H2 2016
  • Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Vulvovaginal Candidiasis - Dormant Projects, H2 2016
  • Vulvovaginal Candidiasis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Vulvovaginal Candidiasis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top